Physician profile
Daniel Laieta
NPI 1437129293
$4,206.30
in general payments reported to CMS, 2019-2025
31 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $416 · 2021: $579 · 2022: $751 · 2023: $1,073 · 2024: $430 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.60 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.85 | 2019-2023 | |
| Lilly USA, LLC | $446.06 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $365.64 | 2019-2022 | |
| Amarin Pharma, INC. | $355.93 | 2019-2022 | |
| Novo Nordisk INC | $253.88 | 2019-2024 | Rybelsus |
| Astrazeneca Pharmaceuticals LP | $249.34 | 2019-2024 | Farxiga, Airsupra |
| Astellas Pharma US INC | $221.95 | 2019-2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $213.64 | 2019-2025 | |
| Allergan, INC. | $183.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.99 | 2020-2023 | Trintellix |
| Exact Sciences Corporation | $148.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $144.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.56 | 2019-2023 | Jardiance |
| Amgen INC. | $102.01 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $95.98 | 2023 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.11 | 2021-2022 | |
| Inspire Medical Systems, INC. | $86.19 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $60.94 | 2020-2024 | Spravato |
| Axsome Therapeutics, INC. | $56.98 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.74 | 2023 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $44.14 | 2021-2023 | Livalo, Seglentis |
| Sanofi Pasteur INC. | $42.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $41.47 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $24.43 | 2020 | |
| Eisai INC. | $19.86 | 2021 | |
| Corcept Therapeutics | $19.71 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $19.23 | 2022 | |
| Esperion Therapeutics, INC. | $18.00 | 2021 | |
| Seqirus USA INC | $17.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Laieta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.